What is the prevalence of Pigmented villonodular synovitis?
How many people does Pigmented villonodular synovitis affect? Does it have the same prevalence in men and women? And in the different countries?
Pigmented villonodular synovitis (PVNS) is a rare benign condition affecting the synovial lining of joints, tendons, and bursae. It is characterized by the abnormal growth of pigmented villonodular tissue which can cause pain, swelling, and limited joint mobility. PVNS can occur in any joint, but it most commonly affects the knee. The prevalence of PVNS is estimated to be around 1.8 cases per million people. Although it is considered rare, PVNS can significantly impact the quality of life for those affected.
Pigmented villonodular synovitis (PVNS) is a rare benign condition that affects the synovial lining of joints, tendon sheaths, and bursae. It is characterized by the abnormal growth of synovial tissue, leading to the formation of nodules or villi.
The prevalence of PVNS is relatively low, making it a rare condition. It is estimated to affect approximately 1.8 to 2.6 individuals per million population. Although it can occur at any age, PVNS most commonly affects adults between the ages of 20 and 50, with a slight female predominance.
While the exact cause of PVNS is unknown, it is believed to be related to an abnormal immune response or genetic factors. The condition can affect any joint in the body, but it most commonly occurs in the knee, followed by the hip and ankle.
Individuals with PVNS may experience symptoms such as joint pain, swelling, stiffness, and limited range of motion. If left untreated, PVNS can lead to joint damage and functional impairment.
Early diagnosis and treatment are crucial in managing PVNS. Treatment options include surgical removal of the affected synovial tissue, radiation therapy, and targeted drug therapy. Regular follow-up and monitoring are necessary to detect any recurrence or progression of the condition.
